Back to top
more

Agios Pharmaceuticals (AGIO)

(Delayed Data from NSDQ)

$42.02 USD

42.02
191,073

-0.03 (-0.07%)

Updated Jul 3, 2024 01:00 PM ET

After-Market: $41.99 -0.03 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (150 out of 249)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Agios Pharmaceuticals (AGIO) Surges 6.5%: Is This an Indication of Further Gains?

by Zacks Equity Research

Agios Pharmaceuticals (AGIO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Prestige Consumer Healthcare (PBH) Down 0.4% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Prestige Consumer Healthcare (PBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Agios (AGIO) Up 21% on Upbeat Data From 2nd Thalassemia Study

by Zacks Equity Research

Data from a late-stage study shows that transfusion-dependent thalassemia patients who received Agios' (AGIO) Pyrukynd demonstrated a statistically significant reduction in transfusion burden.

Agios (AGIO) Up 23% on Selling Brain Cancer Drug Royalty

by Zacks Equity Research

Agios Pharmaceuticals (AGIO) agrees to sell to Royalty Pharma the rights to royalties on potential net sales of a brain cancer drug that was sold to Servier in 2021.

Are Medical Stocks Lagging Lantheus (LNTH) This Year?

by Zacks Equity Research

Here is how Lantheus Holdings (LNTH) and Agios Pharmaceuticals (AGIO) have performed compared to their sector so far this year.

How Much Upside is Left in Agios Pharmaceuticals (AGIO)? Wall Street Analysts Think 26.43%

by Zacks Equity Research

The mean of analysts' price targets for Agios Pharmaceuticals (AGIO) points to a 26.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts See a 26.01% Upside in Agios Pharmaceuticals (AGIO): Can the Stock Really Move This High?

by Zacks Equity Research

The consensus price target hints at a 26% upside potential for Agios Pharmaceuticals (AGIO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Agios (AGIO) Q1 Earnings Surpass, Sales Miss Estimates

by Zacks Equity Research

Agios (AGIO) reports mixed earnings results for first-quarter 2024. Though sales miss the mark, revenues from its sole marketed drug, Pyrukynd, rise sequentially and on a yearly basis.

Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 11.59% and 2.56%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Agios (AGIO) Q4 Earnings & Revenues Fall Short of Estimates

by Zacks Equity Research

Agios' (AGIO) earnings and revenues miss estimates in the fourth quarter of 2023. Revenues from its sole marketed drug, Pyrukynd, rise year over year.

Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -4.88% and 9.84%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Drug, Biotech Stock Q4 Earnings Due on Feb 15: ALNY, BPMC & More

by Zacks Equity Research

Let's look at five biotech/drug companies, ALNY, BPMC, AGIO, CORT and RARE, slated to release quarterly results on Feb 15.

Earnings Preview: Agios Pharmaceuticals (AGIO) Q4 Earnings Expected to Decline

by Zacks Equity Research

Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Agios (AGIO) Up 5% on Upbeat Data From Thalassemia Study

by Zacks Equity Research

Data from a late-stage study shows that non-transfusion-dependent thalassemia patients who received Agios' (AGIO) mitapivat demonstrated a statistically significant increase in hemoglobin response.

Biotech Stock Roundup: VYGR Gains From NVS Deal, AGIO Up on Study Data & More

by Zacks Equity Research

Collaboration news from Voyager (VYGR) and study updates from Agios (AGIO) are the key highlights this week.

Agios Pharmaceuticals (AGIO) Soars 5.2%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Agios Pharmaceuticals (AGIO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Agios (AGIO) Meets Clinical Proof-of-Concept in Anemia Treatment

by Zacks Equity Research

Data from a phase IIa study shows that 40% of patients with low transfusion burden who received Agios' (AGIO) investigational PK activator drug met the transfusion independence endpoint.

Agios (AGIO) Reports Narrower-Than-Expected Q3 Loss, Lags Sales

by Zacks Equity Research

Agios' (AGIO) Q3 earnings beat estimates, but sales miss the same.

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FBT

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

by Zacks Equity Research

Sector ETF report for FBT

Why Is Haemonetics (HAE) Down 1.9% Since Last Earnings Report?

by Zacks Equity Research

Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Alnylam (ALNY) Q2 Loss Wider Than Expected, Revenues Miss

by Zacks Equity Research

Alnylam (ALNY) reports weaker-than-expected second-quarter results. The company also provides updates on its pipeline candidates, which are being developed in collaboration with other pharma bigwigs.

Agios (AGIO) Q2 Earnings Beat Estimates, Revenues In Line

by Zacks Equity Research

Agios (AGIO) reports narrower-than-expected loss in the second quarter of 2023. The revenues are in line with the Zacks Consensus Estimate.